Filings · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelectSM, a
Piper Sandler analyst Kashy Harrison maintains Codexis (NASDAQ:CDXS) with a Overweight and lowers the price target from $9 to $8.
Codexis (NASDAQ:CDXS) affirms FY2026 sales outlook from $72.000 million-$76.000 million to $72.000 million-$76.000 million vs $74.099 million estimate.
Codexis (NASDAQ:CDXS) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.14) by 7.14 percent. This is a 18.75 percent increase over losses of $(0.16) per share from the same